Absci Strengthens ABS-201 Hair Loss Program with Leading Dermatology Experts
核心洞察
Absci has appointed world-renowned dermatologists Dr. Rodney Sinclair and Dr. David Goldberg to its ABS-201 Scientific Advisory Board to guide clinical development of the AI-designed therapeutic for androgenetic alopecia (搜索).
ABS-201 targets prolactin receptors (搜索) to stimulate hair follicle regeneration and demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models.
Phase 1/2a clinical trials are planned to begin in early 2026, with initial proof-of-concept data expected in the second half of 2026 for this potential treatment addressing 80 million Americans with hair loss.
Absci Corporation has strengthened its ABS-201 hair loss program by appointing two world-renowned dermatologists to its Scientific Advisory Board. Dr. Rodney Sinclair and Dr. David Goldberg will guide the clinical development of ABS-201, Absci's flagship AI-designed therapeutic antibody for androgenetic alopecia (搜索), as the company prepares to enter clinical trials in early 2026.
Addressing a Significant Unmet Medical Need
Androgenetic alopecia (搜索), commonly known as male-pattern or female-pattern hair loss, affects approximately 80 million Americans alone. The condition causes crown balding and receding hairlines in men, and progressive hair thinning in women. Currently, the only FDA-approved treatments—minoxidil and finasteride—show limited efficacy and notable side effects, leaving patients with limited therapeutic options.
ABS-201 represents a novel therapeutic approach targeting prolactin receptors (搜索) to stimulate hair follicle regeneration and promote durable hair regrowth as demonstrated in in vivo studies. In preclinical studies, the antibody demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models.
Expert Leadership for Clinical Development
Dr. Rodney Sinclair, MBBS, MD, FACD, is the Professor of Dermatology at the University of Melbourne and Director of Sinclair Dermatology in Melbourne. He is a world-renowned expert in hair loss, with over three decades dedicated to research, clinical practice, and patient advocacy. Dr. Sinclair has authored over 1000 publications including contributions to key textbooks in dermatology and hair disorders.
"Having researched hair loss for over three decades, I've seen the substantial impact androgenetic alopecia (搜索) has on patients' quality of life and self-esteem," said Dr. Sinclair. "ABS-201 has a novel mechanism of action and a promising preclinical profile with the potential for a durable therapy to address a condition where all currently available treatments require continuous usage. I look forward to building on Absci's momentum and innovation."
Dr. David J. Goldberg, MD, JD, has nearly four decades of clinical dermatology experience, with particular expertise in laser therapy and cosmetic dermatology. He is Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai and has performed pivotal research studies in dermatology and hair loss including the original Minoxidil trials. Dr. Goldberg has published more than 200 academic papers and contributed to over 15 textbooks on hair restoration and dermatology.
"Having been involved in research on hair loss for many years, including the original minoxidil trials, low-level light and PRP treatments, I've seen both the achievements and limitations of current therapies. ABS-201's approach is rooted in sound science and early data that show real promise. I'm honored to work with Absci's talented team to help bring innovative, effective solutions to patients suffering from androgenetic alopecia (搜索)," said Dr. Goldberg.
Clinical Development Timeline
Phase 1/2a clinical trials are planned to begin in early 2026, with initial proof-of-concept data expected in the second half of 2026. The company's CEO Sean McClain emphasized the value of the new advisory board members: "Dr. Sinclair and Dr. Goldberg bring world-class expertise to our hair-regrowth program. Their deep understanding of androgenetic alopecia (搜索) and its treatment challenges will be invaluable as we rapidly advance ABS-201 toward clinical validation as a potential best-in-class therapy."
With the expansion of the ABS-201 Scientific Advisory Board, Drs. Sinclair and Goldberg join a distinguished roster of renowned experts in dermatology and hair restoration, including Drs. Anthony Rossi, Maria Hordinsky, Ken Washenik among others.
AI-Driven Drug Discovery Platform
Absci's approach leverages its Integrated Drug Creation™ platform, which combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. The company's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation, with each cycle refining data and strengthening models to facilitate rapid innovation and enhance the precision of therapeutic designs.